NCT03807128 MYeloma Resistance And Clonal Evolution
| NCT ID | NCT03807128 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Nantes University Hospital |
| Condition | Multiple Myeloma |
| Study Type | OBSERVATIONAL |
| Enrollment | 1,400 participants |
| Start Date | 2019-02-11 |
| Primary Completion | 2034-02-11 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 1,400 participants in total. It began in 2019-02-11 with a primary completion date of 2034-02-11.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Multiple Myeloma (MM) is often associated with progression, temporary response to therapy and a high relapse rate over time resulting in a poor long-term prognosis. Because MM is classified as an incurable disease, therapeutic resistance is of great interest. However, knowledge about the biological mechanisms underlying resistance associated with MM therapies and about associated predictors remains poor. The MYRACLE cohort, a multicenter prospective cohort of patients with MM, is set up to address this limitation.
Eligibility Criteria
Inclusion Criteria: * Patient consulting due to the discovery or recurrence of MM according to international diagnostic criteria (IMWG 2014) * Patient having consented to participate in the study and his/her biocollection * Patient affiliated to or benefiting from a social security scheme or similar Exclusion Criteria: * Minors * Major under guardianship or curatorship * Protected persons. * Pregnant or breast-feeding women * Persons benefiting from the AME
Contact & Investigator
Cyrille TOUZEAU, PU
PRINCIPAL INVESTIGATOR
Nantes University Hospital
Frequently Asked Questions
Who can join the NCT03807128 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Multiple Myeloma. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT03807128 currently recruiting?
Yes, NCT03807128 is actively recruiting participants. Contact the research team at cyrille.touzeau@chu-nantes.fr for enrollment information.
Where is the NCT03807128 trial being conducted?
This trial is being conducted at La Roche-sur-Yon, France, Nantes, France.
Who is sponsoring the NCT03807128 clinical trial?
NCT03807128 is sponsored by Nantes University Hospital. The principal investigator is Cyrille TOUZEAU, PU at Nantes University Hospital. The trial plans to enroll 1,400 participants.